SCHEMBL683098

SCHEMBL683098

CCOC(=O)[C@@H]1CCCN1C(=O)CS

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 3/20 0.53
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 3/20 0.40
ACE P12821 3/20 0.40
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CACNA1A O00555 1/20 0.40
CACNA2D1 P54289 1/20 0.40
CACNB1 Q02641 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
F2 P00734 1/20 0.40
REN P00797 1/20 0.40
LTA4H P09960 1/20 0.40
MAPT P10636 1/20 0.40
PEPD P12955 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683426 0.88 FKBP1A (0.51) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL4186372 0.87 FKBP1A (0.56) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL4189488 0.87 FKBP1A (0.56) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6883997 0.84 FKBP1A (0.53) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL5496862 0.84 FKBP1A (0.53) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL5496855 0.84 FKBP1A (0.53) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL683797 0.84 POLB (0.52) FKBP1AALDH1A1HSD17B10ACELMNA
SCHEMBL23135883 0.83 FKBP1A (0.52) FKBP1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL468912 0.82 FKBP1A (0.57) FKBP1AALDH1A1MEN1KMT2AKDM4E
SCHEMBL3529714 0.82 FKBP1A (0.57) FKBP1AALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS BRAINCELLS INC. (US) 2011-02-24 US disclosed
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS BRAINCELLS INC. (US) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS GAP43, GABRB1, GABRB3 FKBP1A 1039/4885ALDH1A1 1041/4885MEN1 3647/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF FKBP1A 1111/4885ALDH1A1 1565/4885MEN1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.